272.2K XNAS Volume
XNAS 17 Mar, 2025 1:04 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| James E. Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2025 | 332,621 | 1,295,117 | - | - | Stock Options | |
| Mark Erlander | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2025 | 758,400 | 2,925,098 | - | - | Stock Options | |
| Fairooz Kabbinavar | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2025 | 150,000 | 780,008 | - | - | Stock Options | |
| Tod Smeal | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2025 | 332,621 | 979,805 | - | - | Stock Options | |
| James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.83 per share. | 16 Dec 2024 | 2,564 | 62,564 (0%) | 0% | 3.8 | 9,820 | Common Stock |
| Levine James E. | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.42 per share. | 16 Dec 2024 | 2,752 | 65,316 (0%) | 0% | 5.4 | 14,905 | Common Stock |
| James Levine E. | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.00 per share. | 16 Dec 2024 | 2,400 | 67,716 (0%) | 0% | 5 | 12,000 | Common Stock |
| Renee P. Tannenbaum | Director | Purchase of securities on an exchange or from another person at price $ 3.42 per share. | 12 Dec 2024 | 10,000 | 20,000 (0%) | 0% | 3.4 | 34,224 | Common Stock |
| Gary W. Pace | Director | Purchase of securities on an exchange or from another person at price $ 2.60 per share. | 11 Dec 2024 | 11,500 | 1,059,376 (10%) | 0% | 2.6 | 29,900 | Common Stock |
| Gary W. Pace | Director | Purchase of securities on an exchange or from another person at price $ 2.60 per share. | 11 Dec 2024 | 350,115 | 1,047,876 (10%) | 3% | 2.6 | 910,299 | Common Stock |
| Gary W. Pace | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 29,700 | 146,974 | - | - | Stock Options | |
| James O. Armitage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 29,700 | 146,974 | - | - | Stock Options | |
| Rodney S. Markin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 29,700 | 182,027 | - | - | Stock Options | |
| Renee P. Tannenbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 29,700 | 128,201 | - | - | Stock Options | |
| Lale White | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 29,700 | 146,974 | - | - | Stock Options | |
| Mani Mohindru | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 29,700 | 128,201 | - | - | Stock Options | |
| James E. Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 205,008 | 962,496 | - | - | Stock Options | |
| Mark Erlander | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 510,000 | 2,170,310 | - | - | Stock Options | |
| Fairooz Kabbinavar | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 205,008 | 630,008 | - | - | Stock Options | |
| Tod Smeal | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 205,008 | 647,184 | - | - | Stock Options | |
| Pace Gary W. | Director | Purchase of securities on an exchange or from another person at price $ 1.37 per share. | 19 Dec 2023 | 30,000 | 697,761 (6%) | 0% | 1.4 | 41,100 | Common Stock |
| Gary W. Pace | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 27,700 | 117,274 | - | - | Stock Options | |
| James O. Armitage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 27,700 | 117,274 | - | - | Stock Options | |
| Rodney S. Markin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 27,700 | 152,327 | - | - | Stock Options | |
| Renee P. Tannenbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 27,700 | 98,501 | - | - | Stock Options | |
| Lale White | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 27,700 | 117,274 | - | - | Stock Options | |
| Mani Mohindru | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 27,700 | 98,501 | - | - | Stock Options | |
| James E. Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 197,472 | 757,488 | - | - | Stock Options | |
| Mark Erlander | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 482,064 | 1,664,477 | - | - | Stock Options | |
| Vicki Kelemen | Exec. VP and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 125,520 | 698,304 | - | - | Stock Options | |
| Tod Smeal | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 167,088 | 442,176 | - | - | Stock Options | |
| Mark Erlander | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.43 per share. | 25 Nov 2022 | 10,000 | 24,481 (0%) | 0% | 1.4 | 14,300 | Common Stock |
| Lale White | Director | Purchase of securities on an exchange or from another person at price $ 1.64 per share. | 19 Sep 2022 | 15,000 | 113,788 (1%) | 0% | 1.6 | 24,525 | Common Stock |
| James O. Armitage | Director | Purchase of securities on an exchange or from another person at price $ 1.56 per share. | 16 Sep 2022 | 13,000 | 13,000 (0%) | 0% | 1.6 | 20,233 | Common Stock |
| James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.56 per share. | 16 Sep 2022 | 30,000 | 60,000 (0%) | 0% | 1.6 | 46,710 | Common Stock |
| Gary W. Pace | Director | Purchase of securities on an exchange or from another person at price $ 1.71 per share. | 15 Sep 2022 | 150,000 | 644,811 (6%) | 1% | 1.7 | 256,500 | Common Stock |
| Renee P. Tannenbaum | Director | Purchase of securities on an exchange or from another person at price $ 1.72 per share. | 15 Sep 2022 | 3,600 | 10,000 (0%) | 0% | 1.7 | 6,192 | Common Stock |
| Renee P. Tannenbaum | Director | Purchase of securities on an exchange or from another person at price $ 1.72 per share. | 15 Sep 2022 | 6,400 | 6,400 (0%) | 0% | 1.7 | 10,976 | Common Stock |
| Lale White | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jul 2022 | 28,858 | 60,716 | - | - | Stock Options | |
| Lale White | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.60 per share. | 05 Jul 2022 | 28,858 | 98,788 (0%) | 0% | 2.6 | 75,031 | Common Stock |
| John Patrick Brancaccio | Former Director | Other type of transaction at price $ 0.00 per share. | 09 Jun 2022 | 44,734 | 125,317 | - | - | Stock Options | |
| John Patrick Brancaccio | Former Director | Other type of transaction at price $ 0.00 per share. | 09 Jun 2022 | 26,800 | 125,317 | - | - | Stock Options | |
| John Patrick Brancaccio | Former Director | Other type of transaction at price $ 0.00 per share. | 09 Jun 2022 | 22,000 | 125,317 | - | - | Stock Options | |
| John Patrick Brancaccio | Former Director | Other type of transaction at price $ 0.00 per share. | 09 Jun 2022 | 28,858 | 125,317 | - | - | Stock Options | |
| John Patrick Brancaccio | Former Director | Other type of transaction at price $ 0.00 per share. | 09 Jun 2022 | 755 | 125,317 | - | - | Stock Options | |
| John Patrick Brancaccio | Former Director | Other type of transaction at price $ 0.00 per share. | 09 Jun 2022 | 530 | 125,317 | - | - | Stock Options | |
| John Patrick Brancaccio | Former Director | Other type of transaction at price $ 0.00 per share. | 09 Jun 2022 | 223 | 125,317 | - | - | Stock Options | |
| John Patrick Brancaccio | Former Director | Other type of transaction at price $ 0.00 per share. | 09 Jun 2022 | 223 | 125,317 | - | - | Stock Options | |
| John Patrick Brancaccio | Former Director | Other type of transaction at price $ 0.00 per share. | 09 Jun 2022 | 195 | 125,317 | - | - | Stock Options | |
| Gary W. Pace | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 26,800 | 89,574 | - | - | Stock Options | |
| James O. Armitage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 26,800 | 89,574 | - | - | Stock Options | |
| Rodney S. Markin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 26,800 | 124,627 | - | - | Stock Options | |
| John Patrick Brancaccio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 26,800 | 125,317 | - | - | Stock Options | |
| James E. Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 170,016 | 560,016 | - | - | Stock Options | |
| Renee P. Tannenbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 26,800 | 70,801 | - | - | Stock Options | |
| Mark Erlander | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 370,128 | 1,185,400 | - | - | Stock Options | |
| Lale White | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 26,800 | 89,574 | - | - | Stock Options | |
| Mani Mohindru | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 26,800 | 70,801 | - | - | Stock Options | |
| Vicki Kelemen | Exec. VP and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 170,016 | 572,784 | - | - | Stock Options | |
| Katherine Ruffner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 170,016 | 370,016 | - | - | Stock Options | |
| Gary W. Pace | Director | Purchase of securities on an exchange or from another person at price $ 6.75 per share. | 21 Sep 2021 | 30,000 | 494,811 (4%) | 0% | 6.8 | 202,500 | Common Stock |
| James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.62 per share. | 10 Sep 2021 | 5,000 | 5,000 (0%) | 0% | 6.6 | 33,100 | Common Stock |
| James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.32 per share. | 10 Sep 2021 | 5,000 | 30,000 (0%) | 0% | 6.3 | 31,600 | Common Stock |
| James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.35 per share. | 10 Sep 2021 | 5,000 | 25,000 (0%) | 0% | 6.4 | 31,750 | Common Stock |
| James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.38 per share. | 10 Sep 2021 | 10,000 | 20,000 (0%) | 0% | 6.4 | 63,800 | Common Stock |
| James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.75 per share. | 10 Sep 2021 | 5,000 | 10,000 (0%) | 0% | 6.8 | 33,750 | Common Stock |
| James E. Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2021 | 390,000 | 390,000 | - | - | Common Stock | |
| Katherine Ruffner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2021 | 200,000 | 200,000 | - | - | Stock Options | |
| Gary S. Jacob | Former Director | Other type of transaction at price $ 0.00 per share. | 10 Jun 2021 | 293 | 76,106 | - | - | Stock Options | |
| Gary S. Jacob | Former Director | Other type of transaction at price $ 0.00 per share. | 10 Jun 2021 | 44,734 | 76,106 | - | - | Stock Options | |
| Gary S. Jacob | Former Director | Other type of transaction at price $ 0.00 per share. | 10 Jun 2021 | 755 | 76,106 | - | - | Stock Options | |
| Gary S. Jacob | Former Director | Other type of transaction at price $ 0.00 per share. | 10 Jun 2021 | 530 | 76,106 | - | - | Stock Options | |
| Gary S. Jacob | Former Director | Other type of transaction at price $ 0.00 per share. | 10 Jun 2021 | 223 | 76,106 | - | - | Stock Options | |
| Gary S. Jacob | Former Director | Other type of transaction at price $ 0.00 per share. | 10 Jun 2021 | 223 | 76,106 | - | - | Stock Options | |
| Gary S. Jacob | Former Director | Other type of transaction at price $ 0.00 per share. | 10 Jun 2021 | 218 | 76,106 | - | - | Stock Options | |
| Gary S. Jacob | Former Director | Other type of transaction at price $ 0.00 per share. | 10 Jun 2021 | 28,858 | 76,106 | - | - | Stock Options | |
| Rodney S. Markin | Director | Purchase of securities on an exchange or from another person at price $ 10.32 per share. | 26 Mar 2021 | 2,900 | 23,879 (0%) | 0% | 10.3 | 29,933 | Common Stock |
| Gary S. Jacob | Director | Purchase of securities on an exchange or from another person at price $ 10.40 per share. | 23 Mar 2021 | 470 | 21,922 (0%) | 0% | 10.4 | 4,886 | Common Stock |
| Gary S. Jacob | Director | Purchase of securities on an exchange or from another person at price $ 10.42 per share. | 23 Mar 2021 | 1,900 | 21,452 (0%) | 0% | 10.4 | 19,804 | Common Stock |
| Gary W. Pace | Director | Purchase of securities on an exchange or from another person at price $ 10.31 per share. | 23 Mar 2021 | 2,500 | 464,811 (4%) | 0% | 10.3 | 25,775 | Common Stock |
| Gary W. Pace | Director | Purchase of securities on an exchange or from another person at price $ 10.21 per share. | 23 Mar 2021 | 2,500 | 462,311 (4%) | 0% | 10.2 | 25,525 | Common Stock |
| Gary W. Pace | Director | Purchase of securities on an exchange or from another person at price $ 10.20 per share. | 23 Mar 2021 | 5,000 | 459,811 (4%) | 0% | 10.2 | 51,000 | Common Stock |
| Mark Erlander | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 10.34 per share. | 23 Mar 2021 | 965 | 14,481 (0%) | 0% | 10.3 | 9,980 | Common Stock |
| Vicki Kelemen | Exec. VP and COO | Purchase of securities on an exchange or from another person at price $ 10.31 per share. | 23 Mar 2021 | 960 | 6,053 (0%) | 0% | 10.3 | 9,898 | Common Stock |
| John Patrick Brancaccio | Director | Purchase of securities on an exchange or from another person at price $ 10.95 per share. | 22 Mar 2021 | 3,000 | 12,260 (0%) | 0% | 11.0 | 32,850 | Common Stock |
| James O. Armitage | Director | Purchase of securities on an exchange or from another person at price $ 10.82 per share. | 19 Mar 2021 | 4,000 | 14,490 (0%) | 0% | 10.8 | 43,271 | Common Stock |
| Gary W. Pace | Director | Purchase of securities on an exchange or from another person at price $ 10.58 per share. | 18 Mar 2021 | 1,000 | 452,811 (4%) | 0% | 10.6 | 10,580 | Common Stock |
| Gary W. Pace | Director | Purchase of securities on an exchange or from another person at price $ 10.54 per share. | 18 Mar 2021 | 2,000 | 454,811 (4%) | 0% | 10.5 | 21,080 | Common Stock |
| Gary W. Pace | Director | Purchase of securities on an exchange or from another person at price $ 9.27 per share. | 04 Mar 2021 | 1,500 | 451,811 (4%) | 0% | 9.3 | 13,898 | Common Stock |
| Mark Erlander | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 02 Jan 2021 | 113 | 13,516 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2021 | 260 | 0 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2021 | 260 | 13,629 (0%) | 0% | 0 | Common Stock | |
| Vicki Kelemen | Exec. VP and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2021 | 70 | 5,124 (0%) | 0% | 0 | Common Stock | |
| Vicki Kelemen | Exec. VP and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2021 | 70 | 0 | - | - | Restricted Stock Units | |
| Vicki Kelemen | Exec. VP and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 02 Jan 2021 | 31 | 5,093 (0%) | 0% | 0 | Common Stock | |
| Vicki Kelemen | Exec. VP and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 23 Nov 2020 | 35,321 | 40,375 (0%) | 0% | 2.5 | 87,596 | Common Stock |
| Vicki Kelemen | Exec. VP and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2020 | 35,321 | 70,641 | - | - | Stock Options | |
| Vicki Kelemen | Exec. VP and COO | Sale of securities on an exchange or to another person at price $ 18.60 per share. | 23 Nov 2020 | 35,321 | 5,054 (0%) | 0% | 18.6 | 657,020 | Common Stock |
| Gary W. Pace | Director | Purchase of securities on an exchange or from another person at price $ 5.71 per share. | 16 Sep 2020 | 850 | 450,311 (4%) | 0% | 5.7 | 4,854 | Common Stock |
| Gary W. Pace | Director | Purchase of securities on an exchange or from another person at price $ 5.69 per share. | 16 Sep 2020 | 1,700 | 449,461 (4%) | 0% | 5.7 | 9,673 | Common Stock |
| Gary S. Jacob | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 28,858 | 76,106 | - | - | Stock Options | |
| Gary W. Pace | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 28,858 | 40,774 | - | - | Stock Options | |
| James O. Armitage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 28,858 | 40,774 | - | - | Stock Options | |
| Rodney S. Markin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 28,858 | 75,827 | - | - | Stock Options | |
| John Patrick Brancaccio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 28,858 | 76,517 | - | - | Stock Options | |
| Thomas H. Adams | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 173,145 | 477,870 | - | - | Stock Options | |
| Mark Erlander | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 221,241 | 380,200 | - | - | Stock Options | |
| Lale White | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 28,858 | 40,774 | - | - | Stock Options | |
| Gary S. Jacob | Director | Purchase of securities on an exchange or from another person at price $ 1.43 per share. | 14 May 2020 | 17,483 | 19,552 (0%) | 0% | 1.4 | 25,001 | Common Stock |
| James O. Armitage | Director | Purchase of securities on an exchange or from another person at price $ 1.43 per share. | 14 May 2020 | 10,490 | 10,490 (0%) | 0% | 1.4 | 15,001 | Common Stock |
| Rodney S. Markin | Director | Purchase of securities on an exchange or from another person at price $ 1.43 per share. | 14 May 2020 | 20,979 | 28,160 (0%) | 0% | 1.4 | 30,000 | Common Stock |
| John Patrick Brancaccio | Director | Purchase of securities on an exchange or from another person at price $ 1.43 per share. | 14 May 2020 | 6,993 | 9,260 (0%) | 0% | 1.4 | 10,000 | Common Stock |
| Thomas H. Adams | Director | Purchase of securities on an exchange or from another person at price $ 1.43 per share. | 14 May 2020 | 13,986 | 18,875 (0%) | 0% | 1.4 | 20,000 | Common Stock |
| Mark Erlander | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.43 per share. | 14 May 2020 | 6,993 | 13,369 (0%) | 0% | 1.4 | 10,000 | Common Stock |
| Lale White | Director | Purchase of securities on an exchange or from another person at price $ 1.43 per share. | 14 May 2020 | 69,930 | 69,930 (0%) | 0% | 1.4 | 100,000 | Common Stock |
| Gary W. Pace | Director | Purchase of securities on an exchange or from another person at price $ 1.34 per share. | 11 May 2020 | 447,761 | 447,761 (4%) | 4% | 1.3 | 600,000 | Common Stock |
| Gary W. Pace | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2020 | 11,916 | 11,916 | - | - | Stock Options | |
| James O. Armitage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2020 | 11,916 | 11,916 | - | - | Stock Options | |
| Lale White | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2020 | 11,916 | 11,916 | - | - | Stock Options | |
| Mark Erlander | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 02 Jan 2020 | 116 | 6,376 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2020 | 261 | 260 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2020 | 261 | 6,492 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Jan 2020 | 552 | 6,231 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2020 | 1,250 | 521 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2020 | 1,250 | 6,783 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2019 | 1,250 | 1,771 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Oct 2019 | 466 | 5,533 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2019 | 1,250 | 5,999 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2019 | 1,250 | 5,210 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2019 | 1,250 | 3,021 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Jul 2019 | 461 | 4,749 (0%) | 0% | 0 | Common Stock | |
| Gary S. Jacob | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 44,734 | 48,071 | - | - | Stock Options | |
| Rodney S. Markin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 44,734 | 46,969 | - | - | Stock Options | |
| John P. Brancaccio | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 44,734 | 47,806 | - | - | Stock Options | |
| Thomas H. Adams | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 298,230 | 304,725 | - | - | Stock Options | |
| Mark Erlander | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 134,203 | 158,959 | - | - | Stock Options | |
| Athena Countouriotis | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 44,734 | 46,019 | - | - | Stock Options | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2019 | 1,250 | 4,419 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2019 | 1,250 | 4,271 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Apr 2019 | 459 | 3,960 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2019 | 1,563 | 33,125 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 02 Jan 2019 | 698 | 19,010 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2019 | 1,563 | 19,708 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2019 | 7,500 | 21,180 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2019 | 7,500 | 34,688 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Jan 2019 | 3,035 | 18,145 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Oct 2018 | 2,731 | 13,680 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2018 | 7,500 | 16,411 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2018 | 7,500 | 42,188 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2018 | 45,000 | 49,688 | - | - | Restricted Stock Units | |
| Rodney S. Markin | None | Purchase of securities on an exchange or from another person at price $ 0.85 per share. | 20 Jun 2018 | 41,200 | 43,085 (0%) | 0% | 0.9 | 35,020 | Common Stock |
| John P. Brancaccio | None | Purchase of securities on an exchange or from another person at price $ 0.80 per share. | 08 Jun 2018 | 10,000 | 13,598 (0%) | 0% | 0.8 | 8,000 | Common Stock |
| Stanley Neal Tennant | None | Purchase of securities on an exchange or from another person at price $ 0.80 per share. | 08 Jun 2018 | 10,000 | 28,839 (0%) | 0% | 0.8 | 8,000 | Common Stock |
| William J. Welch | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2018 | 130,000 | 150,000 | - | - | Restricted Stock Units | |
| William J. Welch | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2018 | 130,000 | 904,655 (1%) | 0% | 0 | Common Stock | |
| William J. Welch | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 30 Jan 2018 | 62,010 | 842,645 (1%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 30 Jan 2018 | 42,930 | 104,367 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2018 | 90,000 | 147,297 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2018 | 90,000 | 56,250 | - | - | Restricted Stock Units | |
| Gary S. Jacob | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 54,322 | 248,101 | - | - | Stock Options | |
| Rodney S. Markin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 54,322 | 160,658 | - | - | Stock Options | |
| John P. Brancaccio | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 54,322 | 246,130 | - | - | Stock Options | |
| Thomas H. Adams | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 54,322 | 467,277 | - | - | Stock Options | |
| William J. Welch | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 662,500 | 1,412,500 | - | - | Stock Options | |
| Stanley Neal Tennant | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 54,322 | 185,586 | - | - | Stock Options | |
| Paul R. Billings | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 54,322 | 175,658 | - | - | Stock Options | |
| Mark Erlander | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 672,189 | 1,782,189 | - | - | Stock Options | |
| Athena Countouriotis | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2018 | 54,322 | 92,428 | - | - | Stock Options | |
| Gary S. Jacob | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 16,667 | 148,954 (20%) | 2% | 0 | Common Stock | |
| Gary S. Jacob | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 16,667 | 0 | - | - | Restricted Stock Units | |
| Rodney S. Markin | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 16,667 | 22,610 (0%) | 0% | 0 | Common Stock | |
| Rodney S. Markin | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 16,667 | 0 | - | - | Restricted Stock Units | |
| John P. Brancaccio | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 16,667 | 0 | - | - | Restricted Stock Units | |
| John P. Brancaccio | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 16,667 | 43,167 (5%) | 2% | 0 | Common Stock | |
| Thomas H. Adams | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 16,667 | 0 | - | - | Restricted Stock Units | |
| Thomas H. Adams | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 16,667 | 351,959 (48%) | 2% | 0 | Common Stock | |
| William J. Welch | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 02 Jan 2018 | 25,487 | 774,655 (105%) | 3% | 0 | Common Stock | |
| William J. Welch | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 50,000 | 280,000 | - | - | Restricted Stock Units | |
| William J. Welch | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 50,000 | 800,142 (109%) | 6% | 0 | Common Stock | |
| Stanley Neal Tennant | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 16,667 | 0 | - | - | Restricted Stock Units | |
| Stanley Neal Tennant | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 16,667 | 226,061 (30%) | 2% | 0 | Common Stock | |
| Paul R. Billings | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 16,667 | 23,165 (0%) | 0% | 0 | Common Stock | |
| Paul R. Billings | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 16,667 | 0 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 18,750 | 66,855 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 18,750 | 146,250 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 02 Jan 2018 | 9,558 | 57,297 (0%) | 0% | 0 | Common Stock | |
| Gary S. Jacob | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2017 | 38,106 | 193,779 | - | - | Stock Options | |
| Rodney S. Markin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2017 | 38,106 | 106,336 | - | - | Stock Options | |
| John P. Brancaccio | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2017 | 38,106 | 191,808 | - | - | Stock Options | |
| Thomas H. Adams | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2017 | 38,106 | 412,955 | - | - | Stock Options | |
| Stanley Neal Tennant | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2017 | 38,106 | 131,264 | - | - | Stock Options | |
| Paul R. Billings | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2017 | 38,106 | 121,336 | - | - | Stock Options | |
| Stanley Neal Tennant | None | Sale of securities on an exchange or to another person at price $ 0.69 per share. | 05 Sep 2017 | 8,334 | 209,394 (0%) | 0% | 0.7 | 5,750 | Common Stock |
| Gary S. Jacob | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2017 | 9,287 | 16,667 | - | - | Restricted Stock Units | |
| Gary S. Jacob | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2017 | 9,287 | 132,287 (0%) | 0% | 0 | Common Stock | |
| Rodney S. Markin | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2017 | 5,943 | 5,943 (0%) | 0% | 0 | Common Stock | |
| Rodney S. Markin | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2017 | 5,943 | 16,667 | - | - | Restricted Stock Units | |
| John P. Brancaccio | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2017 | 12,667 | 16,667 | - | - | Restricted Stock Units | |
| John P. Brancaccio | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2017 | 12,667 | 26,500 (0%) | 0% | 0 | Common Stock | |
| Thomas H. Adams | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2017 | 8,806 | 16,667 | - | - | Restricted Stock Units | |
| Thomas H. Adams | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2017 | 8,806 | 335,292 (0%) | 0% | 0 | Common Stock | |
| Stanley Neal Tennant | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2017 | 8,484 | 16,667 | - | - | Restricted Stock Units | |
| Stanley Neal Tennant | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2017 | 8,484 | 217,878 (0%) | 0% | 0 | Common Stock | |
| Paul R. Billings | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2017 | 6,498 | 16,667 | - | - | Restricted Stock Units | |
| Paul R. Billings | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2017 | 6,498 | 6,498 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 02 Sep 2017 | 12,928 | 48,051 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2017 | 30,001 | 165,000 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2017 | 30,001 | 61,033 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Aug 2017 | 385,000 | 1,110,000 | - | - | Stock Options | |
| William J. Welch | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2017 | 745,392 | 745,392 (2%) | 2% | 0 | Common Stock | |
| William J. Welch | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2017 | 130,000 | 330,000 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2017 | 90,000 | 195,001 | - | - | Restricted Stock Units | |
| Gary S. Jacob | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2017 | 16,667 | 16,667 | - | - | Restricted Stock Units | |
| Gary S. Jacob | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2017 | 9,287 | 25,954 | - | - | Restricted Stock Units | |
| Rodney S. Markin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2017 | 5,943 | 22,610 | - | - | Restricted Stock Units | |
| Rodney S. Markin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2017 | 16,667 | 16,667 | - | - | Restricted Stock Units | |
| John P. Brancaccio | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2017 | 12,667 | 29,334 | - | - | Restricted Stock Units | |
| John P. Brancaccio | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2017 | 16,667 | 16,667 | - | - | Restricted Stock Units | |
| Thomas H. Adams | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2017 | 8,806 | 25,473 | - | - | Restricted Stock Units | |
| Thomas H. Adams | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2017 | 16,667 | 16,667 | - | - | Restricted Stock Units | |
| William J. Welch | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2017 | 200,000 | 200,000 | - | - | Restricted Stock Units | |
| Stanley Neal Tennant | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2017 | 8,484 | 25,151 | - | - | Restricted Stock Units | |
| Stanley Neal Tennant | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2017 | 16,667 | 16,667 | - | - | Restricted Stock Units | |
| Paul R. Billings | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2017 | 6,498 | 23,165 | - | - | Restricted Stock Units | |
| Paul R. Billings | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2017 | 16,667 | 16,667 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 02 Jan 2017 | 23,968 | 31,032 (0%) | 0% | 0 | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2017 | 30,001 | 30,001 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2017 | 50,000 | 0 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2017 | 75,000 | 105,001 | - | - | Restricted Stock Units | |
| Mark Erlander | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2017 | 50,000 | 55,000 (0%) | 0% | 0 | Common Stock | |
| Stanley Neal Tennant | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Dec 2016 | 10,000 | 217,728 | - | - | Common Stock | |
| William J. Welch | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Dec 2016 | 2,250 | 4,750 | - | - | Common Stock | |
| William J. Welch | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Dec 2016 | 2,500 | 2,500 | - | - | Common Stock | |
| Stanley Neal Tennant | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Dec 2016 | 14,966 | 207,728 | - | - | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 14 Dec 2016 | 5,000 | 5,000 | - | - | Common Stock | |
| Mark Erlander | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2016 | 50,000 | 50,000 | - | - | Restricted Stock Units | |
| Stephen Zaniboni | Former CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2016 | 4,514 | 96,968 | - | - | Common Stock | |
| Stephen Zaniboni | Former CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2016 | 166,667 | 76,250 | - | - | Stock Options | |
| Stephen Zaniboni | Former CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2016 | 71,125 | 92,454 | - | - | Common Stock | |
| Stephen Zaniboni | Former CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2016 | 15,000 | 61,250 | - | - | Stock Options | |
| John P. Brancaccio | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2016 | 16,000 | 153,702 | - | - | Stock Options | |
| Gary S. Jacob | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2016 | 16,000 | 155,673 | - | - | Stock Options | |
| Thomas H. Adams | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2016 | 16,000 | 374,849 | - | - | Stock Options | |
| Antonius Schuh | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2016 | 800,000 | 1,858,333 | - | - | Stock Options | |
| Stephen Zaniboni | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2016 | 150,000 | 486,637 | - | - | Stock Options | |
| Rodney S. Markin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2016 | 16,000 | 68,230 | - | - | Stock Options | |
| Stanley Neal Tennant | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2016 | 16,000 | 93,158 | - | - | Stock Options | |
| Matthew L. Posard | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2016 | 150,000 | 650,000 | - | - | Stock Options | |
| Paul R. Billings | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2016 | 16,000 | 83,230 | - | - | Stock Options | |
| Mark Erlander | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2016 | 150,000 | 725,000 | - | - | Stock Options | |
| Antonius Schuh | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 12 Aug 2015 | 20,000 | 20,000 | - | - | Common Stock | |
| Stephen Zaniboni | CFO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 12 Aug 2015 | 15,000 | 21,329 | - | - | Common Stock | |
| Stanley Neal Tennant | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 12 Aug 2015 | 10,000 | 192,762 | - | - | Common Stock | |
| John P. Brancaccio | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2015 | 16,000 | 137,702 | - | - | Stock Options | |
| Gary S. Jacob | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2015 | 16,000 | 139,673 | - | - | Stock Options | |
| Thomas H. Adams | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2015 | 16,000 | 358,849 | - | - | Stock Options | |
| Carl B. Feldbaum | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2015 | 16,000 | 40,000 | - | - | Stock Options | |
| Rodney S. Markin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2015 | 16,000 | 52,230 | - | - | Stock Options | |
| Stanley Neal Tennant | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2015 | 16,000 | 77,158 | - | - | Stock Options | |
| Paul R. Billings | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2015 | 16,000 | 67,230 | - | - | Stock Options | |
| John P. Brancaccio | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2014 | 14,000 | 121,702 | - | - | Stock Options | |
| Gary S. Jacob | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2014 | 15,667 | 123,673 | - | - | Stock Options | |
| Antonius Schuh | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2014 | 175,000 | 1,058,333 | - | - | Stock Options | |
| Stephen Zaniboni | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2014 | 60,000 | 336,637 | - | - | Stock Options | |
| Rodney S. Markin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2014 | 15,667 | 36,230 | - | - | Stock Options | |
| Stanley Neal Tennant | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2014 | 15,667 | 61,158 | - | - | Stock Options | |
| Paul R. Billings | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2014 | 15,667 | 51,230 | - | - | Stock Options | |
| Stephen Zaniboni | CFO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 09 Jun 2014 | 6,329 | 6,329 | - | - | Common Stock | |
| John P. Brancaccio | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2014 | 27,886 | 107,702 | - | - | Stock Options | |
| Gary S. Jacob | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2014 | 21,035 | 108,006 | - | - | Stock Options | |
| Thomas H. Adams | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2014 | 19,568 | 342,849 | - | - | Stock Options | |
| Rodney S. Markin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2014 | 12,230 | 20,563 | - | - | Stock Options | |
| Stanley Neal Tennant | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2014 | 18,588 | 45,491 | - | - | Stock Options | |
| Paul R. Billings | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2014 | 12,230 | 35,563 | - | - | Stock Options | |
| Antonius Schuh | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2013 | 50,000 | 883,333 | - | - | Stock Options | |
| Stephen Zaniboni | Director, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2013 | 50,000 | 276,667 | - | - | Stock Options | |
| Thomas H. Adams | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 30 Aug 2013 | 15,000 | 330,686 | - | - | Common Stock | |
| Thomas H. Adams | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 30 Aug 2013 | 4,200 | 326,486 | - | - | Common Stock | |
| Gabriele M. Cerrone | Other | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2013 | 90,000 | 528,844 | - | - | Stock Options | |
| John P. Brancaccio | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2013 | 23,525 | 79,816 | - | - | Stock Options | |
| Gabriele M. Cerrone | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2013 | 7,832 | 438,844 | - | - | Stock Options | |
| Gary S. Jacob | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2013 | 13,471 | 86,971 | - | - | Stock Options | |
| Thomas H. Adams | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2013 | 12,531 | 323,281 | - | - | Stock Options | |
| Christopher McGuigan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2013 | 7,832 | 16,165 | - | - | Stock Options | |
| Stanley Neal Tennant | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2013 | 11,903 | 26,903 | - | - | Stock Options | |
| Gabriele M. Cerrone | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 10 Dec 2012 | 40,000 | 1,524,498 | - | - | Warrants | |
| Gabriele M. Cerrone | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 10 Dec 2012 | 40,000 | 719,526 | - | - | Common Stock | |
| Stanley Neal Tennant | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 30 Nov 2012 | 25,000 | 161,041 | - | - | Common Stock | |
| Antonius Schuh | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2012 | 200,000 | 833,333 | - | - | Stock Options | |
| Gabriele M. Cerrone | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 17 Aug 2012 | 7,500 | 679,526 | - | - | Common Stock | |
| Gabriele M. Cerrone | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 17 Aug 2012 | 300 | 672,026 | - | - | Common Stock | |
| Gabriele M. Cerrone | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 May 2012 | 15,000 | 671,726 | - | - | Common Stock |